FTC Gives Nod To $4.3B Dainippon-Edison Pharma Deal
The Federal Trade Commission has granted early termination to the required waiting period for a slated $4.3 billion deal between California-based Edison Pharmaceuticals Inc. and Dainippon Sumitomo Pharma Co. Ltd., the...To view the full article, register now.
Already a subscriber? Click here to view full article